PRPF3

Across TCGA pan-cancer cohorts, PRPF3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRPF3 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRPF3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where PRPF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.786	0.947	.004	48	view →
LUAD	OS	Quartile	All	1.000	0.780	.007	26	view →
LSCC	OS	Tertile	II,III,IV	0.941	0.662	.034	6	view →
CCRCC	OS	Median	II,III,IV	0.554	1.000	.025	3	view →
PDAC	DFS	Tertile	IV	0.715	0.199	.024	3	view →
GBM	OS	Median	All	0.564	0.271	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRPF3–HNSC (OS)

Open the HNSC breakdown →